CL2019000245A1 - Moduladores nmda espiro-lactam y métodos de uso de los mismos. - Google Patents
Moduladores nmda espiro-lactam y métodos de uso de los mismos.Info
- Publication number
- CL2019000245A1 CL2019000245A1 CL2019000245A CL2019000245A CL2019000245A1 CL 2019000245 A1 CL2019000245 A1 CL 2019000245A1 CL 2019000245 A CL2019000245 A CL 2019000245A CL 2019000245 A CL2019000245 A CL 2019000245A CL 2019000245 A1 CL2019000245 A1 CL 2019000245A1
- Authority
- CL
- Chile
- Prior art keywords
- nmda
- moduladores
- espiro
- lactam
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pyrrole Compounds (AREA)
Abstract
SE DESCRIBEN COMPUESTOS QUE TIENEN POTENCIA EN LA MODULACIÓN DE LA ACTIVIDAD DEL RECEPTOR DE NMDA. DICHOS COMPUESTOS PUEDEN USARSE EN EL TRATAMIENTO DE AFECCIONES TALES COMO DEPRESIÓN Y TRASTORNOS RELACIONADOS. TAMBIÉN SE DESCRIBEN FORMULACIONES ADMINISTRADAS POR VÍA ORAL Y OTRAS FORMAS DE ADMINISTRACIÓN FARMACÉUTICAMENTE ACEPTABLES DE LOS COMPUESTOS, QUE INCLUYEN FORMULACIONES INTRAVENOSAS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662369529P | 2016-08-01 | 2016-08-01 | |
US201762443915P | 2017-01-09 | 2017-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019000245A1 true CL2019000245A1 (es) | 2019-06-21 |
Family
ID=59593196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019000245A CL2019000245A1 (es) | 2016-08-01 | 2019-01-30 | Moduladores nmda espiro-lactam y métodos de uso de los mismos. |
Country Status (16)
Country | Link |
---|---|
US (6) | US11370790B2 (es) |
EP (1) | EP3490990B1 (es) |
JP (2) | JP2019527232A (es) |
KR (1) | KR102538803B1 (es) |
CN (1) | CN109843889B (es) |
AU (1) | AU2017306164B2 (es) |
BR (1) | BR112019001923A2 (es) |
CA (1) | CA3031563C (es) |
CL (1) | CL2019000245A1 (es) |
CO (1) | CO2019000938A2 (es) |
IL (1) | IL264482B (es) |
MX (1) | MX2019001308A (es) |
PE (1) | PE20190501A1 (es) |
PH (1) | PH12019500208A1 (es) |
SG (1) | SG11201900554YA (es) |
WO (1) | WO2018026798A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102186883B (zh) | 2008-09-18 | 2016-08-03 | 西北大学 | Nmda受体调节剂和其用途 |
LT2951183T (lt) | 2013-01-29 | 2019-05-27 | Aptinyx Inc. | Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas |
EA201990425A1 (ru) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение |
EP3490974B1 (en) | 2016-08-01 | 2023-12-06 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
CA3031537A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
IL286107B1 (en) | 2016-08-01 | 2024-05-01 | Aptinyx Inc | Spiro-lactam NMDA receptor modulators and their uses |
WO2019152696A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
WO2019152685A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and methods of using same |
PE20210455A1 (es) | 2018-01-31 | 2021-03-08 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
MX2022001396A (es) * | 2019-08-01 | 2022-03-25 | Aptinyx Inc | Metodos para tratar trastornos asociados con niveles elevados de anticuerpos que interactuan con el receptor de nmda. |
JP2023505155A (ja) * | 2019-12-04 | 2023-02-08 | アプティニックス インコーポレイテッド | 神経変性疾患に関連する認知障害を治療する方法 |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0180398A1 (en) | 1984-10-26 | 1986-05-07 | The Regents Of The University Of California | Synthesis of beta-lactam |
CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
CA2058975C (en) | 1990-10-30 | 2000-06-06 | Shuichi Kasai | Antiinflammatory gel preparation |
US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
FR2692268B1 (fr) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations. |
SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
DE69731747T2 (de) | 1996-06-07 | 2006-02-02 | Astrazeneca Ab | Peptid derivate |
WO1998005782A1 (en) | 1996-08-02 | 1998-02-12 | Zymogenetics, Inc. | Testis-specific insulin homolog polypeptides |
US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
JP3955345B2 (ja) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | 新規アミノ酸ダイジハーベイン |
AU1585999A (en) | 1997-11-12 | 1999-05-31 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
WO2000027790A1 (en) | 1998-11-11 | 2000-05-18 | Smithkline Beecham P.L.C. | Mutilin compounds |
WO2000028090A2 (en) | 1998-11-12 | 2000-05-18 | Nyxis, Inc. | Diagnostic assay for cancer |
US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
AU1922301A (en) | 1999-11-17 | 2001-05-30 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
EP1255854A2 (en) | 2000-02-01 | 2002-11-13 | Agy Therapeutics, Inc. | Interaction of nmda receptor with protein tyrosine phosphatase |
JP2001261679A (ja) | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬 |
AU2001268467A1 (en) | 2000-06-14 | 2001-12-24 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
CA2413974A1 (en) | 2000-06-22 | 2001-12-27 | Nyxis Neurotherapies, Inc. | Neuroactive peptides for treatment of hypoxia and related conditions |
GB0018272D0 (en) | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
WO2002047535A2 (en) | 2000-12-14 | 2002-06-20 | Nyxis Neurotherapies, Inc. | High throughput assay to detect inhibitors of the map kinase pathway |
WO2002072005A2 (en) | 2001-03-07 | 2002-09-19 | University Of Utah Research Foundation | Linear y-carboxyglutamate rich conotoxins |
WO2002072609A2 (en) | 2001-03-12 | 2002-09-19 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
WO2003010540A1 (en) | 2001-07-25 | 2003-02-06 | Nyxis Neurotherapies, Inc. | Method of identifying nmda-related agent |
DK1519939T5 (da) | 2002-07-05 | 2011-01-24 | Targacept Inc | N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf |
US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
JP2006523704A (ja) | 2003-04-17 | 2006-10-19 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性ヘテロサイクリックシクロペンチルテトラヒドロイソキノリンおよびテトラヒドロピリドピリジンのモジュレーター |
WO2005007656A1 (en) | 2003-07-18 | 2005-01-27 | Virochem Pharma Inc. | Spiro compounds and methods for the modulation of chemokine receptor activity |
US7544478B2 (en) | 2003-08-08 | 2009-06-09 | The Burnham Institute | Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors |
US7662856B2 (en) | 2003-08-29 | 2010-02-16 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
EP1683797A1 (en) | 2003-11-13 | 2006-07-26 | Ono Pharmaceutical Co., Ltd. | Heterocyclic spiro compound |
ATE499373T1 (de) | 2004-01-08 | 2011-03-15 | Hoffmann La Roche | Diazaspiropiperidinderivate |
WO2006034196A1 (en) | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
CN101090902B (zh) | 2004-10-13 | 2013-05-29 | 默沙东公司 | Cgrp受体拮抗剂 |
PL2030622T3 (pl) | 2005-03-24 | 2011-07-29 | Univ Emory | Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu |
US7951912B2 (en) | 2005-08-26 | 2011-05-31 | Wisconsin Alumni Research Foundation | Poly-β-peptides from functionalized β-lactam monomers and antibacterial compositions containing same |
AR059224A1 (es) | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
CN101583612A (zh) | 2006-09-15 | 2009-11-18 | 先灵公司 | 治疗脂质代谢障碍的氮杂环丁酮衍生物 |
JP2008188285A (ja) | 2007-02-06 | 2008-08-21 | Bridgestone Corp | バックパッド及び車両用シート |
CA2682195A1 (en) | 2007-03-20 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
CN101066945B (zh) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | 一种合成3-位取代内酰胺类化合物的方法 |
CN101125817B (zh) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法 |
US20090054392A1 (en) | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
EP2257644B1 (en) | 2008-02-20 | 2015-06-24 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis of autism |
EP2293777B1 (en) * | 2008-06-24 | 2015-02-25 | Intervet International B.V. | Pharmaceutical transdermal compositions and method for treating inflammation in cattle |
EP2313394A1 (en) | 2008-06-27 | 2011-04-27 | NeuroSearch A/S | Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
WO2010015545A1 (en) | 2008-08-07 | 2010-02-11 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
GB0814991D0 (en) | 2008-08-15 | 2008-09-24 | Glaxo Group Ltd | Compounds |
CN102186883B (zh) | 2008-09-18 | 2016-08-03 | 西北大学 | Nmda受体调节剂和其用途 |
WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
DE102009001460B4 (de) | 2009-03-11 | 2010-12-02 | Zf Friedrichshafen Ag | Ölbehälter |
US8329904B2 (en) | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
US20120178695A1 (en) | 2009-07-02 | 2012-07-12 | Joseph Moskal | Methods of treating neuropathic pain |
US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
DK2485751T3 (da) | 2009-10-05 | 2014-08-18 | Univ Northwestern | GLYX-13 til anvendelse i en fremgangsmåde til behandling af upåvirkelig depression |
US8871208B2 (en) | 2009-12-04 | 2014-10-28 | Abbvie Inc. | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof |
CN102762567A (zh) | 2009-12-21 | 2012-10-31 | 诺瓦提斯公司 | 作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类 |
KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도 |
AU2011215704B2 (en) | 2010-02-11 | 2015-07-23 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
US8097634B2 (en) | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
GB201007789D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel Compound |
CN102267995A (zh) | 2010-06-04 | 2011-12-07 | 艾琪康医药科技(上海)有限公司 | 一种制备二氮杂螺环化合物的方法 |
AR082633A1 (es) * | 2010-08-12 | 2012-12-19 | Tetraphase Pharmaceuticals Inc | Analogos de tetraciclina |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
PE20140378A1 (es) * | 2011-02-25 | 2014-03-28 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
PL2686310T3 (pl) | 2011-03-14 | 2018-06-29 | Boehringer Ingelheim International Gmbh | Benzodioksanowe inhibitory wytwarzania leukotrienu |
AU2012249397B2 (en) | 2011-04-27 | 2017-03-30 | Northwestern University | Methods of treating Alzheimer's disease, Huntington's disease, autism, or other disorders |
US9293690B2 (en) | 2011-06-27 | 2016-03-22 | Koninklijke Philips N.V. | Ultrasound transducer assembly and method of manufacturing the same |
EP2734299A4 (en) * | 2011-07-18 | 2016-05-11 | Univ Alberta | CATALYSTS AND METHODS FOR HYDROGENATION OF AMIDES |
SG10201402860QA (en) | 2011-07-27 | 2014-08-28 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
CN103172641B (zh) * | 2011-12-20 | 2014-06-11 | 钱卫 | 杂环胺基烷氧基取代的喹唑啉衍生物及其用途 |
AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
CN102936216B (zh) * | 2012-12-05 | 2015-03-04 | 南京药石药物研发有限公司 | 7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法 |
AU2014212485C1 (en) | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
JP2016506961A (ja) * | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | スピロラクタム系nmda受容体モジュレーターおよびその使用 |
KR20150110784A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
CN105229010A (zh) * | 2013-01-29 | 2016-01-06 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
LT2951183T (lt) | 2013-01-29 | 2019-05-27 | Aptinyx Inc. | Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas |
CN103171641B (zh) | 2013-03-19 | 2015-07-15 | 浙江大学 | 具备轮动功能的弹跳机器人 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
GB2528480A (en) * | 2014-07-23 | 2016-01-27 | Givaudan Sa | Improvements in or relating to organic compounds |
GB201416346D0 (en) | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Spirocyclic derivatives |
CA3024606C (en) | 2016-05-19 | 2019-09-03 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
EP3490974B1 (en) | 2016-08-01 | 2023-12-06 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
EA201990425A1 (ru) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение |
IL286107B1 (en) | 2016-08-01 | 2024-05-01 | Aptinyx Inc | Spiro-lactam NMDA receptor modulators and their uses |
PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
CA3031537A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
BR112020015666A2 (pt) | 2018-01-31 | 2021-02-23 | Aptinyx Inc. | moduladores de espiro-lactamas de receptores nmda e usos dos mesmos |
PE20210455A1 (es) | 2018-01-31 | 2021-03-08 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
US20210308101A1 (en) | 2019-11-11 | 2021-10-07 | Aptinyx Inc. | Methods of treating fibromyalgia |
JP2023505155A (ja) | 2019-12-04 | 2023-02-08 | アプティニックス インコーポレイテッド | 神経変性疾患に関連する認知障害を治療する方法 |
-
2017
- 2017-08-01 PE PE2019000294A patent/PE20190501A1/es unknown
- 2017-08-01 CN CN201780052686.0A patent/CN109843889B/zh active Active
- 2017-08-01 BR BR112019001923-5A patent/BR112019001923A2/pt active Search and Examination
- 2017-08-01 IL IL264482A patent/IL264482B/en unknown
- 2017-08-01 US US16/322,604 patent/US11370790B2/en active Active
- 2017-08-01 SG SG11201900554YA patent/SG11201900554YA/en unknown
- 2017-08-01 AU AU2017306164A patent/AU2017306164B2/en active Active
- 2017-08-01 CA CA3031563A patent/CA3031563C/en active Active
- 2017-08-01 KR KR1020197005659A patent/KR102538803B1/ko active IP Right Grant
- 2017-08-01 JP JP2019505141A patent/JP2019527232A/ja active Pending
- 2017-08-01 MX MX2019001308A patent/MX2019001308A/es unknown
- 2017-08-01 WO PCT/US2017/044871 patent/WO2018026798A1/en unknown
- 2017-08-01 EP EP17751918.8A patent/EP3490990B1/en active Active
-
2018
- 2018-06-12 US US16/006,125 patent/US10150769B2/en active Active
- 2018-11-21 US US16/197,584 patent/US20190330209A1/en not_active Abandoned
-
2019
- 2019-01-28 PH PH12019500208A patent/PH12019500208A1/en unknown
- 2019-01-30 CL CL2019000245A patent/CL2019000245A1/es unknown
- 2019-01-30 CO CONC2019/0000938A patent/CO2019000938A2/es unknown
-
2020
- 2020-02-04 US US16/781,141 patent/US11427585B2/en active Active
-
2022
- 2022-06-03 US US17/831,547 patent/US20230128006A1/en active Pending
- 2022-06-07 JP JP2022092070A patent/JP7448747B2/ja active Active
- 2022-07-28 US US17/875,508 patent/US20230192693A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3490990A1 (en) | 2019-06-05 |
CA3031563C (en) | 2023-12-05 |
US20210002279A1 (en) | 2021-01-07 |
SG11201900554YA (en) | 2019-02-27 |
CA3031563A1 (en) | 2018-02-08 |
WO2018026798A1 (en) | 2018-02-08 |
JP2019527232A (ja) | 2019-09-26 |
IL264482A (en) | 2019-02-28 |
US11370790B2 (en) | 2022-06-28 |
KR102538803B1 (ko) | 2023-06-01 |
CN109843889B (zh) | 2022-03-15 |
JP2022119998A (ja) | 2022-08-17 |
AU2017306164A1 (en) | 2019-01-31 |
IL264482B (en) | 2022-09-01 |
US10150769B2 (en) | 2018-12-11 |
KR20190037275A (ko) | 2019-04-05 |
US11427585B2 (en) | 2022-08-30 |
EP3490990C0 (en) | 2023-12-06 |
US20230128006A1 (en) | 2023-04-27 |
PE20190501A1 (es) | 2019-04-10 |
BR112019001923A2 (pt) | 2019-05-14 |
US20180291023A1 (en) | 2018-10-11 |
PH12019500208A1 (en) | 2019-12-11 |
US20190194200A1 (en) | 2019-06-27 |
JP7448747B2 (ja) | 2024-03-13 |
CO2019000938A2 (es) | 2019-02-08 |
MX2019001308A (es) | 2019-05-30 |
EP3490990B1 (en) | 2023-12-06 |
US20230192693A1 (en) | 2023-06-22 |
US20190330209A1 (en) | 2019-10-31 |
CN109843889A (zh) | 2019-06-04 |
AU2017306164B2 (en) | 2021-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019000245A1 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos. | |
CL2019000248A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
CL2019000247A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
CL2019000249A1 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
CL2019000246A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
CL2017000814A1 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. | |
PE20151416A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PE20151427A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
MX2018012223A (es) | Formulaciones liquidas de fosfaplatino. | |
AR122456A2 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos |